Pay in 4 interest-free payments of $375.00 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Add 5 uL of Annexin V-PE or 10 uL of 7-AAD to the single stain tube and incubate for 5 minutes at room temperature and protect from light
ER α can be used as a tumour marker
This cytokine is produced by activated macrophages as a proprotein
but also as a therapeutic site
Host Rabbit Antigen Vimentin Synonyms VIM Immunogen Synthetic Peptide Location Cytoplasm
ActRIIB Enzyme Activity Inhibitor Screening Kit Cell Proliferation Viability Add 5 uL of AnnexinProduct Specification Background STX 001, the leading program of Supercede, is a novel oral small molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibiting the ACTRII signaling pathway has been proven to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving significant fat
US$ 49.50
US$ 13.00
US$ 17.50
US$ 47.00
US$ 64.50
US$ 57.50
US$ 49.50
US$ 54.50
US$ 39.50
US$ 16.20
US$ 64.50